BioPharmSignal logoBioPharmSignal

Biotech News

Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial Platform

Genenta Science (GNTA)Genenta ScienceCompany update

Nasdaq Ticker to Change to ‘SAEN’ on November 4, 2026 MILAN, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that it will do business as Saentra Forge and that its American Depositary Shares (“ADSs”) are expected to begin trading on the

Related news

GNTAGenenta Science2026-10-21 20:01 EST

Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

FATEFate Therapeutics2026-11-03 21:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

URGNUroGen Pharma2026-10-19 12:00 EST

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

TEVATeva Pharmaceutical Industries2026-10-12 21:45 EST

Teva to Host R&D Day on Wednesday, November 11 in New York City

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

View all latest news

Genenta Science

Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.

Recent company news

GNTAGenenta Science2026-11-02 11:00 EST

Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial Platform

GNTAGenenta Science2026-10-21 20:01 EST

Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification

GNTAGenenta Science2026-09-15 08:10 EST

Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit

GNTAGenenta Science2026-07-23 07:09 EST

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

Stock data

Close
0.99 USD
Market cap
51.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States